Latest Research in Immunotherapy and Immune Responses

Top Research Topics in Immunotherapy and Immune Responses

• CAR-T cell therapy research — 4 papers
• Immunotherapy and Immune Responses — 2 papers
• Liver physiology and pathology — 2 papers
• Monoclonal and Polyclonal Antibodies Research — 2 papers
• Acute Myeloid Leukemia Research — 2 papers
• Radiopharmaceutical Chemistry and Applications — 1 papers
• Immune Cell Function and Interaction — 1 papers
• Glycosylation and Glycoproteins Research — 1 papers
• Myeloproliferative Neoplasms: Diagnosis and Treatment — 1 papers

Highest-Cited Papers

1. Personalized neoantigen vaccine platform and longitudinal tracking of vaccine-related clonotypes enable the identification of tumor-specific TCRs
2. A Dual-Ligand PDC Co-Targeting FOLR1 and c-Met Enhances Tumor Accumulation and Antitumor Efficacy in Ovarian Cancer
3. Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1
4. Immune Toxicities After CAR-T and Bispecific T-Cell Engager Therapies
5. A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial
6. Antibody-Radionuclide Conjugates for Solid Tumors: Multidimensional Strategies from Component Engineering to Synergistic Combination Therapy
7. Development and in vitro characterization of a bispecific TCR-like antibody targeting the PRAME301–309/HLA-A*24:02 complex for cancer immunotherapy
8. The type I FLT3 inhibitor XL999 overrides secondary FLT3-ITD mutations that arise under gilteritinib and quizartinib treatment in acute myeloid leukemia
9. Effective Tumor Protection by a Tumor-Associated Mucin-1 Glycopeptide-Based Conjugate Vaccine in a Spontaneous Mouse Breast Cancer Model
10. Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study
11. Rational Engineering of Notch1 Signaling to Boost the Proliferation of CD19-BBζ CAR-T
12. Breast cancer prevention by prophylactic Lalba mRNA-LNP vaccination
13. The Trispecific Antibody IBI3019 Integrates CDH17-Enhanced EGFR Antagonism with Optimized CD16A Engagement to Elicit Potent Antitumor Activity with Minimal Toxicity
14. Fast tumor accumulation and payload release of c-Met targeting aptamer-drug conjugate enables robust anti-tumor efficacy
15. Optimizing exposure: the case for dose-dense CAR T-cell administration
16. A phase 1 study of VAC85135, a neoantigen vaccine regimen targeting calreticulin and JAK2 mutations, in combination with ipilimumab in patients with myeloproliferative neoplasms